VJOncology is committed to improving our service to you

ESMO WCGIC 2020 | MT-5111: immunotoxin in HER2+ solid tumours

VJOncology is committed to improving our service to you

Zev Wainberg

Zev Wainberg, MD, of Ronald Reagan UCLA Medical Center, Los Angeles, CA, outlines results from a Phase I study evaluating MT-5111, a novel immunotoxin, in HER-2 positive solid tumours. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter